News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Nvidia beat estimates but its shares fell, pressuring the broader semiconductor sector.
  • Trade Desk stock plunged about 16% after issuing a below-consensus Q1 revenue outlook.
  • Technology sector forward multiples have fallen to roughly the same level as consumer staples.
  • Bank of America cut 2026 sales and earnings forecasts for China's auto and EV sector due to weaker demand and rising component costs.
  • Russian authorities plan an early-April block on Telegram, likely restricting access outside frontline Ukraine locations.
  • Preparations for a potential Trump-Xi Beijing summit are behind schedule, reducing chances of concrete outcomes.

Latest Articles

TSX Futures Rise as Precious Metals Rebound Boosts Mining and Tech Stocks

TSX Futures Rise as Precious Metals Rebound Boosts Mining and Tech Stocks

Futures tied to Canada’s principal stock index opened higher Monday as gold and silver gains supported a rebound in mining shares and helped Canadian technology stocks recover partially from earlier AI-driven selling. U.S. futures were slightly lower as investors awaited delayed U.S. employment and consumer price index data and a fresh wave of corp…

Ralliant Director Adds $99,825 in Stock as Shares Trade Near 52-Week Low

Ralliant Director Adds $99,825 in Stock as Shares Trade Near 52-Week Low

Ralliant Corp director Brian Worrell bought 2,500 shares of common stock on February 6, 2026, for $99,825 at a weighted average price of $39.93. The purchase occurred as the stock traded near its 52-week low and after a recent $1.44 billion non-cash goodwill impairment tied to EA Elektro-Automatik. Analysts' price targets and ratings on Ralliant va…

U.S. Container Imports Fall 6.8% in January as China Shipments Drop Sharply

U.S. Container Imports Fall 6.8% in January as China Shipments Drop Sharply

U.S. seaports handled 6.8% fewer container imports in January versus the prior year, according to Descartes Systems Group. The month saw 2,318,722 TEUs overall, a figure above the historical average that Descartes attributes to steadier demand rather than the frontloading that drove January 2025’s record. Imports from China fell 22.7% to 771,093 TE…

B3 divulga funcionamento da bolsa durante o Carnaval

B3 divulga funcionamento da bolsa durante o Carnaval

A B3 comunicou os horários de operação da bolsa para o período do Carnaval. Não haverá pregão para os mercados de renda variável nos dias 16 (segunda) e 17 (terça). Na Quarta-Feira de Cinzas (18) as negociações ocorrerão em regime de meio período, com horários específicos para pré-abertura, sessão contínua e call de fechamento, além de horários dif…

Stifel Flags Young’s and Fuller's as Top UK Pub Picks as Market Recovers

Stifel Flags Young’s and Fuller's as Top UK Pub Picks as Market Recovers

Stifel identifies the UK pubs sector as undervalued yet fundamentally robust heading into 2026, naming Young & Co’s Brewery and Fuller Smith & Turner as its top stock picks. Both companies receive Buy recommendations - Young’s with a 1,450p target and Fuller’s at 750p - supported by premium estate positioning, freehold-backed balance sheets, margin…

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright Lifts Biogen Price Target to $228, Citing Pipeline Diversification and Key Clinical Catalysts

H.C. Wainwright increased its price target on Biogen to $228 from $194 and reaffirmed a Buy rating, pointing to a broadened drug pipeline across renal, lupus and SMA indications. The firm highlighted the felzartamab AMR program, upcoming LEQEMBI IQLIK PDUFA and SPINRAZA High-Dose adoption as drivers that could shift Biogen's revenue mix despite ong…

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush Starts Coverage on Zura Bio with Outperform, $15 Target

Wedbush has begun coverage of Zura Bio Ltd. with an Outperform rating and a $15.00 price objective, noting clinical readouts and pipeline progress as key upside drivers. The stock trades well below the target but above InvestingPro's Fair Value estimate, and the company announced a CEO appointment effective January 21, 2026.

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Pulls Compounded GLP-1 Pill, BTIG Keeps Buy Rating

Hims & Hers Health has stopped offering its recently introduced compounded semaglutide pill following industry and regulatory discussions. The move follows signals from the FDA about enforcement against non-approved GLP-1 drugs. Despite the product withdrawal and a recent share-price decline, BTIG has maintained a Buy rating with a $60 price target…